Mark Toms profile: Article on joint-working

Building a healthier future for our NHS through joint working

In a resource-scarce and budget-strained environment, Joint Working Projects between the NHS and the pharmaceutical industry are helping to meet the healthcare challenges of...
SMC accepts letermovir for use within NHS Scotland for appropriate patients.

Achieving value in the NHS through partnership

How AbbVie’s ‘Decisions with Value’ initiative brought healthcare experts together to tackle the challenge of improving health outcomes while making savings. Over recent years the NHS...
The Topol Review and innovative technologies in the NHS

Advancing electronic prescribing

The Electronic Prescription Service (EPS) sends electronic prescriptions from GP surgeries to pharmacies and currently accounts for around 64% of all prescriptions issued in...
Chris Molloy from Medicines Discovery Catapult

Medicines Discovery Catapult and the high impact medicines discovery

Chris Molloy is the Chief Executive Officer of the Medicines Discovery Catapult (MDC). He joined the organisation two years ago as only the second...
Lucy Jones - Doctors of the World

Doctors of the World: Healthcare for everyone

Lucy Jones, Director of Programmes at Doctors of the World UK, supports access to healthcare for excluded people around the world. She joined the...
Lynda Bailey and Sarah Davies on managing the menopause at work

Managing the menopause at work

Every woman will go through the menopause, so why is it rarely discussed openly in a work environment? A significant cultural shift is required in...
Dmitry Schourov on uniting traditional and digital marketing

Uniting traditional and digital marketing

Dmitry Schourov is Strategy and Commercial Operations Director at Pfizer Russia, responsible for full strategic support of the business and all operational support including...
paper aeroplanes illustrating the rise of biosimilars

Rise of the biosimilars

2018 was a significant year for biosimilars. October’s patent expiry of adalimumab, the world’s top selling prescription medicine, saw a raft of biosimilars launch,...
Woman walking up stairs. political response to the NHS 10 year plan

Politics and the NHS Long Term Plan

Claudia Rubin looks at the immediate political response to the NHS 10 Year Plan which launched in January. Politics always moves at an incredible pace as...
IV drip in a hospital setting. PPRS evolution

PPRS evolution and what does it mean for pharma?

How has the Pharmaceutical Price Regulation Scheme (PPRS) evolved since its inception in the 1950s, and what does its latest iteration mean for pharma? Price...

Latest articles

Oral health has been isolated from traditional healthcare and health policy for too long fuelling an oral health crisis according to a Lancet Series.

Big Sugar and neglect by global health community fuel oral health crisis 

Oral health has been isolated from traditional healthcare and health policy for too long, despite the major global public health burden of oral diseases,...
New statistics show decrease in animals used for R&D

New statistics show decrease in animals used for R&D

The Home Office has released its annual statistics on animals used in research in Great Britain. It shows 3.52 million procedures were carried out...
New insight into microRNA function has been published by scientists at the University of Eastern Finland and the University of Oxford.

New insight into microRNA function can give gene therapy a boost

New insight into microRNA function has been published by scientists at the University of Eastern Finland and the University of Oxford. They have shown that...

Popular articles

pain relief patch released by nurofen

Nurofen launches a 24 hour ibuprofen pain relief patch

Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen.  Despite body pain being among the most commonly...
NICE has approved a first-in-class gene silencing therapy for hereditary amyloidosis.

Gene silencing therapy for hereditary amyloidosis approved by NICE

NICE has approved a first-in-class gene silencing therapy for hereditary amyloidosis. RNA interference (RNAi) therapeutics company, Alnylam UK Limited has welcomed a decision from the...
AstraZeneca to appeal NICE's osimertinib decision

AstraZeneca to appeal NICE’s osimertinib decision

AstraZeneca to appeal NICE's osimertinib decision following it not being recommended for use within NHS England. AstraZeneca will appeal a decision by the National Institute...

Top 5 R&D hubs in the UK

Read this cover story in the June issue of Pf Magazine here.    Join us on a tour of inspirational research and development centres. ...

How to write a standout CV

The job market is getting more competitive by the day, as highly-qualified candidates fiercely compete for the top jobs. A carefully constructed CV is...